Last reviewed · How we verify
A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma
This is a study designed to evaluate the efficacy and safety of oral YY-20394 in patients with R/R follicular non-Hodgkin's lymphoma who have failed at least two prior systemic therapies.
Details
| Lead sponsor | Shanghai YingLi Pharmaceutical Co. Ltd. |
|---|---|
| Phase | PHASE2 |
| Status | UNKNOWN |
| Enrolment | 123 |
| Start date | Mon Apr 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Feb 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Lymphoma, Follicular
Interventions
- YY-20394
Countries
China